{"name":"UCB SA","slug":"ucb","ticker":"UCBJY","exchange":"OTC","domain":"ucb.com","description":"UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company offers Cimzia for ankylosing spondylitis (AS), axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, polyarticular juvenile idiopathic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; and Neupro for Parkinson's disease and restless legs syndrome. It also provides Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. In addition, the company offers Evenity for the treatment of osteoporosis in postmenopausal women; Bimzelx to treat plaque psoriasis, psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis; Fintepla for the treatment of Dravet and Lennox-Gastaut syndrome; and RYSTIGGO and ZILBRYSQ to treat people living with generalized myasthenia gravis. Further, it develops KYGE","hq":"Brussels, Belgium","founded":2004,"employees":"9765","ceo":"Jean-Christophe Tellier","sector":"Specialty Pharma","stockPrice":154.28,"stockChange":0.28,"stockChangePercent":0.18,"marketCap":"$58.8B","metrics":{"revenue":7741000192,"revenueGrowth":26.6,"grossMargin":74.3,"rdSpend":0,"netIncome":1558000000,"cash":2363000064,"dividendYield":0.51,"peRatio":33.3,"fiscalYear":"FY2026"},"revenueBreakdown":[{"name":"Cimzia","genericName":"CERTOLIZUMAB PEGOL","slug":"certolizumab-pegol","revenue":1600000000,"yoyGrowth":0,"percentOfTotal":45.1},{"name":"Bimzelx","genericName":"BIMEKIZUMAB","slug":"bimekizumab","revenue":1200000000,"yoyGrowth":0,"percentOfTotal":33.9},{"name":"Briviact","genericName":"BRIVARACETAM","slug":"brivaracetam","revenue":400000000,"yoyGrowth":0,"percentOfTotal":11.3},{"name":"Amphetamine Sulfate","genericName":"amfetamine","slug":"amfetamine","revenue":172000000,"yoyGrowth":0,"percentOfTotal":4.9},{"name":"Xelstrym","genericName":"dexamfetamine","slug":"dexamfetamine","revenue":172000000,"yoyGrowth":0,"percentOfTotal":4.9}],"timeline":[{"date":"1955-01-01","label":"Amphetamine Sulfate first approved","drug":"Amphetamine Sulfate","drugSlug":"amfetamine","type":"approval","sentiment":"positive"},{"date":"1955-01-01","label":"Xelstrym first approved","drug":"Xelstrym","drugSlug":"dexamfetamine","type":"approval","sentiment":"positive"},{"date":"2007-01-01","label":"Neupro first approved","drug":"Neupro","drugSlug":"rotigotine","type":"approval","sentiment":"positive"},{"date":"2008-01-01","label":"Cimzia first approved","drug":"Cimzia","drugSlug":"certolizumab-pegol","type":"approval","sentiment":"positive"},{"date":"2016-01-01","label":"Briviact first approved","drug":"Briviact","drugSlug":"brivaracetam","type":"approval","sentiment":"positive"},{"date":"2020-01-01","label":"Fintepla first approved","drug":"Fintepla","drugSlug":"fenfluramine","type":"approval","sentiment":"positive"},{"date":"2025-01-01","label":"Kygevvi first approved","drug":"Kygevvi","drugSlug":"doxribtimine","type":"approval","sentiment":"positive"},{"date":"2025-01-01","label":"Kygevvi first approved","drug":"Kygevvi","drugSlug":"doxecitine","type":"approval","sentiment":"positive"},{"date":"2026-06-30","label":"Kygevvi PHASE2 readout","drug":"Kygevvi","drugSlug":"doxribtimine","type":"phase3_readout","sentiment":"neutral"},{"date":"2026-06-30","label":"Kygevvi PHASE2 readout","drug":"Kygevvi","drugSlug":"doxecitine","type":"phase3_readout","sentiment":"neutral"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2028-12-31","label":"Vimpat Phase 3 readout (Non-Convulsive Status Epilepticus)","drug":"Vimpat","drugSlug":"lacosamide","type":"phase3_readout","sentiment":"neutral"},{"date":"2029-11-22","label":"BIMZELX Phase 3 readout (Palmoplantar Pustulosis)","drug":"BIMZELX","drugSlug":"bimekizumab-bkzx","type":"phase3_readout","sentiment":"neutral"},{"date":"2030-04-09","label":"Briviact patent expiry (Formulation)","drug":"Briviact","drugSlug":"brivaracetam","type":"patent_expiry","sentiment":"negative"},{"date":"2040-06-05","label":"Vimpat patent expiry (Formulation)","drug":"Vimpat","drugSlug":"lacosamide","type":"patent_expiry","sentiment":"negative"},{"date":"2040-06-05","label":"Vimpat patent expiry (Formulation)","drug":"Vimpat","drugSlug":"lacosamide","type":"patent_expiry","sentiment":"negative"},{"date":"2040-06-05","label":"Vimpat patent expiry (Formulation)","drug":"Vimpat","drugSlug":"lacosamide","type":"patent_expiry","sentiment":"negative"},{"date":"2028-06-01","label":"Cimzia patent cliff ($1.5B at risk)","drug":"Cimzia","type":"patent_expiry","sentiment":"negative"},{"date":"2030-06-01","label":"Vimpat patent cliff ($500M at risk)","drug":"Vimpat","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":1600000000,"percentOfTotal":45.1,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Cimzia","genericName":"CERTOLIZUMAB PEGOL","slug":"certolizumab-pegol","indication":"Ankylosing spondylitis","status":"marketed","revenue":1600000000}]},{"name":"Immunology","slug":"immunology","revenue":1200000000,"percentOfTotal":33.9,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"Bimzelx","genericName":"BIMEKIZUMAB","slug":"bimekizumab","indication":"Erythrodermic psoriasis","status":"marketed","revenue":1200000000},{"name":"BIMZELX","genericName":"BIMEKIZUMAB-BKZX","slug":"bimekizumab-bkzx","indication":"Moderate to severe plaque psoriasis","status":"marketed"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":400000000,"percentOfTotal":11.3,"drugCount":4,"colorKey":"cardiovascular","drugs":[{"name":"Briviact","genericName":"BRIVARACETAM","slug":"brivaracetam","indication":"Partial seizure","status":"marketed","revenue":400000000},{"name":"Fintepla","genericName":"FENFLURAMINE","slug":"fenfluramine","indication":"Dravet syndrome","status":"marketed"},{"name":"Neupro","genericName":"ROTIGOTINE","slug":"rotigotine","indication":"Parkinson's disease","status":"marketed"},{"name":"Vimpat","genericName":"lacosamide","slug":"lacosamide","indication":"Idiopathic generalized epilepsy","status":"marketed"}]},{"name":"Other","slug":"other","revenue":172000000,"percentOfTotal":4.9,"drugCount":4,"colorKey":"infectious","drugs":[{"name":"Xelstrym","genericName":"dexamfetamine","slug":"dexamfetamine","indication":"Attention deficit hyperactivity disorder","status":"marketed","revenue":172000000},{"name":"Kygevvi","genericName":"DOXRIBTIMINE","slug":"doxribtimine","indication":"Thymidine Kinase 2 Deficiency","status":"marketed"},{"name":"Kygevvi","genericName":"DOXECITINE","slug":"doxecitine","indication":"thymidine kinase 2 deficiency (TK2d)","status":"marketed"},{"name":"RYSTIGGO","genericName":"ROZANOLIXIZUMAB-NOLI","slug":"rozanolixizumab-noli","indication":"Generalized myasthenia gravis","status":"marketed"}]},{"name":"Metabolic","slug":"metabolic","revenue":172000000,"percentOfTotal":4.9,"drugCount":1,"colorKey":"neuroscience","drugs":[{"name":"Amphetamine Sulfate","genericName":"amfetamine","slug":"amfetamine","indication":"Attention deficit hyperactivity disorder","status":"marketed","revenue":172000000}]}],"pipeline":[{"name":"Cimzia","genericName":"CERTOLIZUMAB PEGOL","slug":"certolizumab-pegol","phase":"marketed","mechanism":"Certolizumab pegol binds to and neutralizes human TNFα, reducing inflammation without causing antibody-dependent cell-mediated cytotoxicity.","indications":["Ankylosing spondylitis","Crohn's disease","Erythrodermic psoriasis","Plaque psoriasis","Psoriasis with arthropathy"],"catalyst":""},{"name":"Bimzelx","genericName":"BIMEKIZUMAB","slug":"bimekizumab","phase":"marketed","mechanism":"Bimzelx works by binding to interleukin-17A, a protein that promotes inflammation, to reduce symptoms of psoriasis.","indications":["Erythrodermic psoriasis","Plaque psoriasis","Pustular psoriasis"],"catalyst":""},{"name":"Briviact","genericName":"BRIVARACETAM","slug":"brivaracetam","phase":"marketed","mechanism":"Briviact works by binding to the synaptic vesicle glycoprotein 2A, reducing the release of neurotransmitters and stabilizing neuronal activity.","indications":["Partial seizure"],"catalyst":""},{"name":"Amphetamine Sulfate","genericName":"amfetamine","slug":"amfetamine","phase":"marketed","mechanism":"Sodium-dependent dopamine transporter","indications":["Attention deficit hyperactivity disorder","Narcolepsy","Obesity"],"catalyst":""},{"name":"Xelstrym","genericName":"dexamfetamine","slug":"dexamfetamine","phase":"marketed","mechanism":"Xelstrym works by blocking the reuptake of noradrenaline, allowing it to stay in the brain for longer and increasing alertness and focus.","indications":["Attention deficit hyperactivity disorder","Narcolepsy"],"catalyst":""},{"name":"Kygevvi","genericName":"DOXRIBTIMINE","slug":"doxribtimine","phase":"marketed","mechanism":"Kygevvi works by replacing the deficient enzyme thymidine kinase 2 in patients with TK2d.","indications":["Thymidine Kinase 2 Deficiency"],"catalyst":""},{"name":"BIMZELX","genericName":"BIMEKIZUMAB-BKZX","slug":"bimekizumab-bkzx","phase":"marketed","mechanism":"Interleukin-17A, Interleukin-17F, Interleukin-17AF","indications":["Moderate to severe plaque psoriasis","Active psoriatic arthritis","Active non-radiographic axial spondyloarthritis","Active ankylosing spondylitis","Moderate to severe hidradenitis suppurativa"],"catalyst":""},{"name":"Fintepla","genericName":"FENFLURAMINE","slug":"fenfluramine","phase":"marketed","mechanism":"Fintepla works by binding to the Alpha-1B adrenergic receptor, which helps regulate the activity of certain neurons in the brain.","indications":["Dravet syndrome","Obesity","Seizures associated with Dravet syndrome"],"catalyst":""},{"name":"Kygevvi","genericName":"DOXECITINE","slug":"doxecitine","phase":"marketed","mechanism":"KYGEVVI incorporates pyrimidine nucleosides into skeletal muscle mitochondrial DNA, restoring mitochondrial DNA copy number.","indications":["thymidine kinase 2 deficiency (TK2d)"],"catalyst":""},{"name":"Neupro","genericName":"ROTIGOTINE","slug":"rotigotine","phase":"marketed","mechanism":"Rotigotine stimulates dopamine receptors in the brain, which may help treat Parkinson's disease and Restless Legs Syndrome.","indications":["Parkinson's disease","Restless legs"],"catalyst":""},{"name":"RYSTIGGO","genericName":"ROZANOLIXIZUMAB-NOLI","slug":"rozanolixizumab-noli","phase":"marketed","mechanism":"IgG receptor FcRn large subunit p51","indications":["Generalized myasthenia gravis"],"catalyst":""},{"name":"Vimpat","genericName":"lacosamide","slug":"lacosamide","phase":"marketed","mechanism":"Dihydropyrimidinase-related protein 2, Carbonic anhydrase 1, Carbonic anhydrase 12","indications":["Idiopathic generalized epilepsy","Partial Epilepsy Treatment Adjunct","Tonic-clonic seizure in patients with epilepsy"],"catalyst":""}],"recentEvents":[{"date":"2024-02-01","type":"earnings","headline":"UCB SA Reports Fourth Quarter and Full Year 2023 Results","summary":"UCB SA reported its fourth quarter and full year 2023 results, with revenue of €3.4 billion and a net loss of €1.1 billion.","drugName":"","sentiment":"neutral"},{"date":"2023-09-01","type":"deal","headline":"UCB SA and Neurocrine Biosciences Announce Collaboration to Develop New Treatments for CNS Disorders","summary":"UCB SA and Neurocrine Biosciences announced a collaboration to develop new treatments for CNS disorders, with a focus on neurodegenerative diseases.","drugName":"","sentiment":"positive"},{"date":"2023-06-01","type":"regulatory","headline":"FDA Approves Cimzia (certolizumab pegol) for the Treatment of Non-Radiographic Axial Spondyloarthritis","summary":"The FDA approved Cimzia (certolizumab pegol) for the treatment of non-radiographic axial spondyloarthritis, expanding the indication for the drug.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxQTUZ6dy12Vktlc3pFOVJjRVlrOUdIeFVrU2tOUnVublhidUJ5U2xFUW40SzNPVnpwdmczeHkwR18yUXZITWY0VnpKTFNCUjZqTXZ2REMxZDJIMHJFVGg5LVdOSzFlSjJISWNvSjdGdHYyUURLNXYzSnN6OFpWM25qN1c5ZlJNcHFEWE8zSEVVM0hDNGFSdk9DczRzbXJtZFNsRUZ5ZXA1bjd4ME53UkE?oc=5","date":"2026-03-31","type":"deal","source":"MarketBeat","summary":"UCB (OTCMKTS:UCBJY) Sees Large Volume Increase - Still a Buy? - MarketBeat","headline":"UCB (OTCMKTS:UCBJY) Sees Large Volume Increase - Still a Buy?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiygFBVV95cUxNOGpTOEFCR1ZjcGpjRmJyYVhIVUlxNnBWczlmZlBIVzlucEhlNXpMdktLUlZ3VjlYUm41ekE2YUNLOEFWSld4REZQRENDeEQ4d3lnREttSGFURkdybl9QWDBVbHh4Qnl5TzZWYUlwVXNta0FWV2x2cHd0RzlYNktsejVIN0NIRHJORTUyR1lGaGFmZENWMTF4ck5xcjFyczB3d29BUnhiLXhqMFkyYnpMX0U1Yzl4XzFVQS1fZ29GTTNNSlpLU0tRcTZ3?oc=5","date":"2026-03-28","type":"pipeline","source":"MarketBeat","summary":"UCB (OTCMKTS:UCBJY) Shares Pass Below 50-Day Moving Average - Here's What Happened - MarketBeat","headline":"UCB (OTCMKTS:UCBJY) Shares Pass Below 50-Day Moving Average - Here's What Happened","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxQdHlUeVFMbXc1ZmRmbzRBaGUyVHZ1WVJ6YVB4a1VMQm1haGVFb0puWHNSYlJhbExtZ3prYnMwUENUbE42S2FuWUlaRklsaTF3U2hkN1d4WG9VVk5iM3lBaUNGS1lqS3NmQWJpMHRCdXYyOVJ1VG5WTi11T1Naa1R1cFlZSWxJNWc3cEZKLWpoYjYwbmU1SUZXa0VVTGt2aHVCTnhQVUFuX0NpYnRHVW9FVnhZLWV0NzhCdzRycENvLXpjc0hHcF9n?oc=5","date":"2026-03-24","type":"pipeline","source":"Seeking Alpha","summary":"UCB Selects Georgia for New U.S. Biologics Manufacturing Facility; ~$5B Economic Impact and ~330 Permanent Jobs - Seeking Alpha","headline":"UCB Selects Georgia for New U.S. Biologics Manufacturing Facility; ~$5B Economic Impact and ~330 Permanent Jobs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxNdUU3aVhfSmc2Q014MmVaS1dMMjlnSlI1bzBvdnVkaHJ3Z0l4amFNa3ZFQnRoc3JfaWFKaVJqQnRuSVd2Q3RjOUZlbm1zc2VhMGZOeHR4VS1zZmltSUVkcmNTRV85MDFmc240OFA5SGFYcGpHTnc2clAtZC1jb2MzMjNBVHlBWm1IbmpEanpYbw?oc=5","date":"2026-03-11","type":"pipeline","source":"Seeking Alpha","summary":"AbbVie’s Skyrizi beaten by UCB’s Bimzelx in psoriatic arthritis - Seeking Alpha","headline":"AbbVie’s Skyrizi beaten by UCB’s Bimzelx in psoriatic arthritis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxPaEdBQzF6c1JhTkQwc0trOWZ3blRoYnRJSDRIRjRpQXhoUjlOSzVKRk9udmhudzdneTI4MUJMVlN3d245RUZEY0RVVlIyMHQ5MkpJaFRwVUdQcnk0RFNmRVBDbUZjTW5HVFNzeWZlcll0X3IyVGQ1U040aUxMSWZzZlM1SUJqSnhVT1pKeUJpLS1UcE9t?oc=5","date":"2026-02-27","type":"earnings","source":"Seeking Alpha","summary":"UCB SA 2025 Q4 - Results - Earnings Call Presentation (OTCMKTS:UCBJY) 2026-02-27 - Seeking Alpha","headline":"UCB SA 2025 Q4 - Results - Earnings Call Presentation (OTCMKTS:UCBJY) 2026-02-27","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxPektDbmFsRldCTmRqOFNkZ0NzcmgwSi1WZmN6N2l5YjJpaWlZclVEak1fUXVVaW9vbmZpcURDV21qblgzTGZCd3dXYW9Od2RiVlJBWUQ0X2xScDljY0NOcDItbkRkdzh2Zll4SXhuM0YwOE1YVlhNUGtsa25fUHNla2lFcGdGbUlyV0JHUFZSdl95LXNXdDAtSUF6Y29QMGtHanFtVExRc2FwN0JIM1RjeThZRFZKdHRZLVNKOHQzaFh0Q0RMNWZN?oc=5","date":"2025-09-29","type":"deal","source":"Investing.com","summary":"TD Cowen reiterates Buy rating on UCB stock, citing Bimzelx potential - Investing.com","headline":"TD Cowen reiterates Buy rating on UCB stock, citing Bimzelx potential","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxNeXRHTjZ0MDdpRTd3aEJZRGQ2RmZWbElVUUJsb0QxMHBsenB5NmhOOEQxYVRscnUzaHZBTUlBUHNvMERCeXMzTGhHOFItQThfMVdPV0I5amJta0xFN0gtTTV5bmdMZGZZVkhTaTFBQ1VJZ2ZtSnpseEpDYnlsVVRLNQ?oc=5","date":"2025-08-22","type":"deal","source":"Yahoo Finance","summary":"All You Need to Know About UCB (UCBJY) Rating Upgrade to Strong Buy - Yahoo Finance","headline":"All You Need to Know About UCB (UCBJY) Rating Upgrade to Strong Buy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiXEFVX3lxTE16WU9BTy1PNWhsVmE2ODJ6MGw2LVZvVDc3Y3U2c2lYbzV3Y0h3ZXJfc2RGNzh0a2RDY0dWRXl6S0JlcHpPSXk0WV9BaUxpckc0clFvUGRQUW5NNmlI?oc=5","date":"2017-11-12","type":"pipeline","source":"MarketBeat","summary":"UCB (UCBJY) Stock Price, News & Analysis - MarketBeat","headline":"UCB (UCBJY) Stock Price, News & Analysis","sentiment":"neutral"}],"patents":[{"drugName":"Cimzia","drugSlug":"certolizumab-pegol","patentNumber":"","type":"Patent Cliff","expiryDate":"2028-06-01","territory":"US","annualRevenue":1500000000},{"drugName":"Briviact","drugSlug":"brivaracetam","patentNumber":"10729653","type":"Formulation","expiryDate":"2030-04-09","territory":"US","annualRevenue":400000000,"genericFilings":[]},{"drugName":"Vimpat","drugSlug":"lacosamide","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":500000000},{"drugName":"Vimpat","drugSlug":"lacosamide","patentNumber":"11337943","type":"Formulation","expiryDate":"2040-06-05","territory":"US","genericFilings":[]},{"drugName":"Vimpat","drugSlug":"lacosamide","patentNumber":"12042474","type":"Formulation","expiryDate":"2040-06-05","territory":"US","genericFilings":[]},{"drugName":"Vimpat","drugSlug":"lacosamide","patentNumber":"11883374","type":"Formulation","expiryDate":"2040-06-05","territory":"US","genericFilings":[]}],"drugCount":12,"phaseCounts":{"marketed":12},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Biogen","Sanofi","Novartis"],"therapeuticFocus":["Central Nervous System (CNS)","Immunology","Bone and Joint Disorders"],"financials":null,"yahoo":{"currentPrice":154.28,"previousClose":154,"fiftyTwoWeekHigh":168.76,"fiftyTwoWeekLow":71.16,"fiftyTwoWeekRange":"71.155 - 168.76","fiftyDayAverage":152.52,"twoHundredDayAverage":132.58,"beta":0.23,"enterpriseValue":29250951168,"forwardPE":19.8,"priceToBook":2.34,"priceToSales":7.59,"enterpriseToRevenue":3.78,"enterpriseToEbitda":11.19,"pegRatio":2.04,"ebitda":2614000128,"ebitdaMargin":33.8,"freeCashflow":1825874944,"operatingCashflow":2291000064,"totalDebt":2244999936,"debtToEquity":20.7,"currentRatio":1.38,"returnOnAssets":7,"returnOnEquity":14.9,"analystRating":"1.0 - Strong Buy","recommendationKey":"strong_buy","numberOfAnalysts":2,"targetMeanPrice":170.56,"targetHighPrice":177.46,"targetLowPrice":163.67,"dividendRate":0.79,"payoutRatio":0.17,"fiveYearAvgDividendYield":1.24,"exDividendDate":1745798400,"insiderHeldPercent":0,"institutionHeldPercent":0,"sharesOutstanding":380722724,"floatShares":119859128,"sharesShort":0,"shortRatio":0,"shortPercentOfFloat":0,"epsTrailing":4.63,"epsForward":7.79,"revenuePerShare":20.36,"bookValue":66.07,"officers":[{"age":66,"name":"Dr. Jean-Christophe  Tellier","title":"CEO & Executive Director"},{"age":59,"name":"Ms. Sandrine  Dufour CFA","title":"Executive VP & CFO"},{"age":58,"name":"Mr. Alistair  Henry","title":"Executive VP & Chief Scientific Officer"},{"age":58,"name":"Ms. Denelle J. Waynick Johnson J.D.","title":"Executive VP & General Counsel"},{"age":60,"name":"Mr. Jean-Luc  Fleurial","title":"Executive VP & Chief Human Resources Officer"},{"age":56,"name":"Mr. Emmanuel  Caeymaex","title":"Executive Vice President of Patient Evidence"},{"age":66,"name":"Dr. Kirsten  Lund-Jurgensen Ph.D.","title":"Executive Vice President of Patient Supply"},{"age":47,"name":"Ms. Fiona  du Monceau","title":"Executive VP of Patient Impact & Chief Commercial Officer"}],"industry":"Biotechnology","irWebsite":"http://www.ucb.com/investors.asp","website":"https://www.ucb.com","phone":"32 2 559 99 99"}}